This inventor holds 3 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Targovax Oy. Active years: 2016-2023.
Location History:
- Riihimaki, FI (2016)
- Riihimäki, FI (2021 - 2023)
Company Filing History:
Years Active: 2016-2023
Title: Tuuli Ranki: Innovator in Cancer Therapy
Introduction
Tuuli Ranki is a notable inventor based in Riihimäki, Finland. He has made significant contributions to the field of cancer therapy, particularly through his innovative approaches involving adenoviruses and checkpoint inhibitors. With a total of 3 patents to his name, Ranki is recognized for his pioneering work in this critical area of medical research.
Latest Patents
One of Tuuli Ranki's latest patents focuses on the combination of adenovirus and checkpoint inhibitors for treating cancer. This invention relates to a combination therapy that utilizes an oncolytic adenovirus vector alongside one or more checkpoint inhibitors. The goal of this therapy is to enhance the effectiveness of cancer treatment by leveraging the unique properties of both the adenovirus and the checkpoint inhibitors.
Career Highlights
Tuuli Ranki is currently associated with Targovax Oy, a company dedicated to developing innovative cancer therapies. His work at Targovax has positioned him as a key player in the advancement of oncolytic virus therapies, which aim to improve patient outcomes in cancer treatment.
Collaborations
Tuuli Ranki collaborates with several talented individuals in his field, including Sari Anneli Pesonen and Magnus Jäderberg. These collaborations enhance the research and development efforts at Targovax, fostering an environment of innovation and discovery.
Conclusion
Tuuli Ranki's contributions to cancer therapy through his patents and work at Targovax Oy highlight his commitment to advancing medical science. His innovative approaches have the potential to significantly impact the treatment of cancer, offering hope to patients worldwide.